Book an appointment

Planning guides

How to get a second opinion from a Chinese specialist (without flying)

Step-by-step guide to remote second opinions from Class A specialists. 7-day workflow, what to submit, costs, and how the recommendation typically differs from home-country care.

← All guides

When a remote second opinion is high-yield

Remote second opinions are particularly valuable for:

  • Cancer diagnoses where domestic Chinese therapies (PD-1 inhibitors, CAR-T, anlotinib, oligomannate, roxadustat) may be options unavailable / unaffordable elsewhere
  • Cases where home-country recommendation feels overly aggressive or under-aggressive
  • Diagnostic uncertainty — the second opinion may identify alternative considerations
  • Pre-flight validation that international travel is worthwhile for treatment
  • Cases where multidisciplinary tumour-board review at a high-volume academic centre would change the plan

What you submit

Standard submission packet:

  • Recent imaging (CT, MRI, PET) — DICOM files preferred, with the radiologist report
  • Pathology slides or scanned images plus the pathology report
  • Recent labs and operative reports
  • Current medication list including prior treatment summaries
  • Brief patient narrative (1–2 paragraphs) describing the case from your perspective

Coordinator collates and translates as needed before routing to the appropriate sub-specialist or multidisciplinary team.

The 7-day workflow

  1. Day 1: Case submission via secure upload
  2. Days 2–3: Coordinator collation, translation, routing
  3. Days 4–6: Senior specialist review; for oncology, multidisciplinary tumour board discussion
  4. Day 7: Written second-opinion report — diagnosis confirmation / revision, treatment plan recommendations, alternative options, structured workup plan if travel elected
  5. Optional: 30–45 minute follow-up video consultation with the reviewing specialist

Cost bands

  • Single-specialist written second opinion: USD 400–800
  • Multidisciplinary remote second opinion (e.g. oncology tumour board): USD 800–1,800
  • Video consultation add-on: USD 200–400 for 30–45 minutes

What you get

  • Formal written report on hospital letterhead
  • Translated documentation suitable for sharing with home-country physician
  • Clear travel-or-don't-travel recommendation if you've asked for one
  • If you elect to travel, a structured workup and treatment plan with itemised cost estimate

For many patients, the most valuable outcome is confirmation of the home-country plan — that itself is worth the fee.

How the recommendation often differs

Common ways a Class A second opinion changes the plan:

  • Access to therapies not available or affordable in the home country
  • Recommendation of a less-invasive approach where home-country recommendation was more aggressive
  • Identification of alternative diagnostic considerations missed in the original workup
  • Clarification of staging that affects treatment intensity
  • Multidisciplinary input (surgery + oncology + radiation + medical) where home-country care was siloed

Frequently asked

How is this different from a regular telehealth consult?
A second opinion is a structured review of your case file by a senior specialist (often with multidisciplinary input for oncology) who returns a written report. A telehealth consult is typically a real-time video visit. Second opinions are higher-investment but more comprehensive.
Is the report accepted by my home-country physician?
Yes — Class A academic hospital second-opinion reports are written in standard medical format with clinical reasoning. Home-country physicians can review and integrate the recommendations into ongoing care. The coordinator translates the report and shares it with your home physician on request.
What if the second opinion confirms my current plan?
Confirmation is itself valuable — many patients use the validation to commit to their existing treatment with confidence. If the plan is confirmed, no travel is needed.

Further reading

Medical Tourism

Telehealth Second Opinions from Class A Hospitals: 7-Day Workflow

Before flying, get a written second opinion from a senior Chinese specialist via telehealth. Here is the standard 7-day workflow, what's included, and what it costs.

Oncology

PD-1 Inhibitors in China: Tislelizumab, Sintilimab, Camrelizumab vs Keytruda

China has approved four major domestic PD-1 inhibitors with strong clinical evidence in multiple tumour types. The cost gap with Keytruda is enormous — but so are the indication differences. Here is the careful comparison.

Oncology

CAR-T at Ruijin and Renji: Approved Indications, Real Outcomes, What to Expect

China has emerged as a global leader in CAR-T cell therapy delivery and clinical research. Here is the current state — approved indications, leading centres, costs, and the realistic outcomes data.

Oncology

Proton vs Heavy Ion vs Photon Therapy in China: When Each Makes Sense

China is one of the few countries with operational heavy-ion therapy alongside proton therapy. Here is how the three modalities differ, where each fits clinically, and what they cost.

Talk to a coordinator

Free 30-minute consult to discuss your case and which hospital pathway fits best.

Book free consult